Scientists across the country are focused on stopping, treating and developing a vaccine against COVID-19. For those things to happen, the science must go on. But how can researchers collaborate at a time when labs are shutting down and there are restrictions on meeting face-to-face? Researchers at the University of Utah’s Immunology, Inflammation & Infectious Disease (3i) Initiative decided to go virtual — with surprising results.
Researchers blame a low-tech skin-pinch test, in part, for the routine failure of potential scleroderma drugs in clinical trials. Modernizing the evaluation of potential drug therapies was the focus of the three-day Scleroderma Diagnosis Sandpit hosted by Scleroderma and Raynaud’s UK February 26-28, 2020 at the Wellcome Collection in London.